Day Zero Diagnostics

We provide unique rapid molecular diagnostic products and services that help to dramatically transform patient care by using precision medicine to guide antibiotic therapy selection and optimize the treatment of life-threatening drug-resistant infections, improve antibiotic stewardship, and decrease the spread of multidrug-resistant microorganisms (MDROs). Our innovative approaches to infectious disease diagnostics consist of highly multiplexed syndromic molecular panels to address the global threat of antimicrobial resistance (AMR). For more information on our products and services:.

Our goal is to provide the necessary tools for doctors and medical staff to make optimal treatment decisions that can ultimately improve public health as a whole. We believe our technology and processes can replace or augment current diagnostic paradigms in a range of settings, such as hospitals, independent diagnostic testing facilities, veterinary and livestock clinics, and research institutions.PathoGene’s patented, fully-automated, sample-to-answer IVD medical device will detect and identify all infectious bacterial, viral, fungal, and parasitic pathogens and profile antimicrobial resistance in clinical samples. Significantly faster and more accurate diagnostic testing improves patient outcomes by reducing hospital length of stay & healthcare costs, lowering risks of long-term complications, and reducing patient mortality. Fully-automated workflows enable untrained laboratory personnel to operate cutting-edge nanopore sequencing technology at a cost comparable to microbiological culture with sensitivity testing. PathoGene's best-in-class diagnostic testing platform will ensure the United States remains prepared for any biosecurity threat, like SARS-COV-2, Monkeypox, filoviruses, anthrax, and other Category A bioterrorism agents.

Together we are working to combat antibiotic resistance through diagnostic innovation. BioAmp will first apply DETECT to direct care of complicated urinary tract infections, delivering results that enable physicians to treat their patients with RIGHT antibiotic the FIRST time. Leadership, product ideation and development support, & partnership liaison (corporate relations and investment). Research scientist leading microbiology testing and clinical research.

GenomeKey is building a world where nobody dies from a treatable infection. We are transforming diagnostics with our next-generation IVD device, which maps the right antibiotic to the right patient, in just hours. We are living through a period of profound technological change. We’re giving clinicians the information they need, much faster, so they can deliver targeted treatment and save more lives. Our device detects bacteria, identifies it, and provides a full AMR profile directly from patient blood, in only hours. Sepsis is a more serious and multifaceted threat than you might realise.

We are a multidisciplinary team of microbiologists and infectious diseases specialists singularly focused on helping solve the antimicrobial resistance crisis by developing new, first-in-class drugs to treat bacterial infections, including those caused by multidrug-resistant pathogens. Backed by some of the leading scientific and business leaders, we feel we are up for this challenge. Our initial product candidates are new agents to treat lethal, resistant infections such as those caused by resistant Gram-negative pathogens like MDR and carbapenem-resistant Acinetobacter baumannii, Pseudomonas aeruginosa and others listed on WHO’s Priority Pathogen List.

Our mission is to empower clinicians with highly accurate and timely diagnostic information in order to improve treatment of patients in the critical early stages of infection. Our bedside test delivers results in 15 minutes - ensuring patients receive the best therapies from the outset.